66.4 Gender-Affirming Primary Care & Hormone Therapy

Principles of Affirming Primary Care & The Organ Inventory

Gender-affirming primary care is centered on evidence-based, compassionate, and patient-centered medicine aligned with the World Professional Association for Transgender Health Standards of Care, Version 8 (WPATH SOC 8) and the Endocrine Society Clinical Practice Guidelines. Family physicians serve as the essential clinical coordinators managing hormone therapy, preventive wellness, and routine chronic illness care.

Clinical Environment & Inclusive Documentation

• Names and Pronouns: Affirming communication requires consistently using the patient's affirmed name and pronouns (e.g., she/her, he/him, they/them) across oral and electronic medical record (EMR) interactions. EMR systems must decouple demographic fields: legal name, chosen name, legal sex marker, sex assigned at birth, and gender identity.
• Trauma-Informed Physical Examination: Invasive examinations (e.g., pelvic exams, breast/chest exams, genital examinations) should be performed only when clinically indicated, with explicit prior explanation, chaperone options, trauma-informed positioning, and smaller pediatric/narrow speculums when severe vaginal atrophy is present.

The "Organ Inventory" Paradigm in Cancer Screening

Routine cancer screening guidelines based strictly on cisgender demographic designations fail to protect transgender patients. The universal primary care principle is:

[!IMPORTANT] The Organ Inventory Rule Screen whatever anatomical organs and tissues are present, regardless of the patient's legal sex marker, gender expression, or gender identity:

• Cervix Present (transgender men who have not undergone total hysterectomy): Follow standard cervical cancer screening guidelines (cervical cytology and high-risk HPV cotesting). Testosterone therapy often induces cervical atrophy, which can increase the rate of "unsatisfactory for evaluation" Pap results; treating with localized vaginal estrogen for 7–14 days prior to repeat sampling improves cellular yield.
• Breast / Chest Tissue Present:
  • Transgender men who have not had bilateral mastectomy ("top surgery"): Routine screening mammography starting at age 40 (per USPSTF guidelines).
  • Transgender men post-mastectomy: If residual breast tissue remains, perform annual clinical chest exams.
  • Transgender women receiving feminizing hormone therapy: After ≥5–10 years of feminizing hormone therapy and reaching age 50, initiate biennial screening mammography due to estrogen-induced breast lobuloalveolar development.
• Prostate Present (transgender women, regardless of whether they have undergone vaginoplasty/orchiectomy): Transgender women retain their prostate gland (the prostate is not removed during gender-affirming vaginoplasty). Engage in shared decision-making regarding PSA screening starting at age 50 (or 40–45 if African American or positive family history). Diagnostic Nuance: Normal female reference ranges for PSA should be used; because anti-androgens and estrogens suppress baseline PSA by approximately 50%, a PSA value $>1.0\text{ ng/mL}$ in a transfeminine patient on hormone suppression warrants urologic investigation.

Gender-Affirming Hormone Therapy (GAHT)

The goal of gender-affirming hormone therapy is to induce secondary sexual characteristics concordant with the patient's affirmed gender while suppressing incongruent endogenous sexual characteristics, keeping systemic hormone concentrations within normal physiological reference ranges for the affirmed gender.

1. Feminizing Hormone Therapy (Transgender Women / Transfeminine Individuals)

Therapeutic Goals

• Suppress endogenous testosterone to the physiological cisgender female range: Total Testosterone $< 50\text{ ng/dL}$.
• Maintain physiological cisgender female estradiol levels: Serum Estradiol 100 to 200\text{ pg/mL}$.
• Clinical phenotypic changes: Breast development (typically Tanner stage II–III), female body fat redistribution (increased hip/buttock fat, decreased abdominal visceral fat), skin softening, decreased facial/body hair growth rate, decreased spontaneous erections and testicular volume, and reduction in androgenic male-pattern balding.

                  FEMINIZING HORMONE THERAPY: DRUGS & DOSAGES

   Drug Class & Agent        Route & Typical Daily Dose          Clinical Advantages & Monitoring Pearls
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   17β-Estradiol (Oral)      • 2.0 to 8.0 mg PO once daily       • Low cost; well tolerated.
                             (or divided twice daily; can be     • Undergoes hepatic first-pass metabolism;
                             administered sublingually)            modest increases in VTE risk in older smokers.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   17β-Estradiol             • 0.1 to 0.4 mg/day patch applied   • PREFERRED FIRST-LINE FOR:
   (Transdermal Patch)         once or twice weekly                - Age > 40 years, tobacco users, obesity
                                                                   - Controlled hypertension, hypertriglyceridemia
                                                                   - Personal/family risk factors for VTE.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Estradiol Valerate or     • 10 to 20 mg IM or subcutaneous    • Avoids daily dosing; provides rapid peak
   Estradiol Cypionate         every 1 to 2 weeks                  estradiol concentrations.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Spironolactone            • 100 to 200 mg PO daily in         • FIRST-LINE ANTI-ANDROGEN IN THE UNITED STATES.
   (Anti-Androgen)             divided doses (50–100 mg BID)     • Blocks androgen receptors; inhibits 17α-hydroxylase.
                                                                 • ADVERSE EFFECTS: Hyperkalemia, polyuria, orthostasis.
                                                                 • MANDATORY: Monitor K+ and Cr at baseline and q3mo.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Finasteride /             • Finasteride 1 to 5 mg PO daily    • 5α-reductase inhibitor; blocks DHT synthesis.
   Dutasteride                 Dutasteride 0.5 mg PO daily       • Useful adjuvant for androgenic alopecia;
                                                                   does NOT lower total testosterone levels.
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

• Laboratory Monitoring in Feminizing GAHT:
  • Check serum estradiol, total testosterone, basic metabolic panel (potassium, BUN, creatinine), and blood pressure every 3 months during the first year, then every 6 to 12 months once stable.
  • Target: Estradiol $100–200\text{ pg/mL}$ (measure at trough if receiving IM injections; avoid drawing blood immediately after sublingual dosing to prevent falsely high spikes).
  • Target: Total testosterone $<50\text{ ng/dL}$.
  • Routine serum prolactin is checked at baseline and periodically if the patient develops galactorrhea, visual changes, or headaches (estrogen stimulates pituitary lactotroph hyperplasia; rare prolactinoma).

2. Masculinizing Hormone Therapy (Transgender Men / Transmasculine Individuals)

Therapeutic Goals

• Elevate serum total testosterone to the physiological cisgender male range: 300 to 1000\text{ ng/dL}$.
• Suppress endogenous ovarian estradiol production.
• Clinical phenotypic changes:
  • Irreversible Changes: Deepening of vocal pitch (vocal cord hypertrophy), clitoromegaly (typically 1–4 cm enlargement), facial and terminal body hair growth, and androgenic male-pattern temporal hair thinning.
  • Reversible Changes: Cessation of menses (amenorrhea typically occurs within 2–6 months), increased lean skeletal muscle mass and strength, upper-body fat redistribution, increased libido, and acne.

                  MASCULINIZING HORMONE THERAPY: DRUGS & DOSAGES

   Formulation & Agent       Route & Typical Dosage              Clinical Administration & Pharmacokinetics
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Testosterone Cypionate    • 50 to 100 mg Subcutaneous         • Weekly administration provides smoother serum levels
   or Enanthate                or IM once weekly, OR               with fewer emotional or energy fluctuations.
                             • 100 to 200 mg IM every 2 weeks    • Subcutaneous injection is equally effective as IM
                                                                   and causes significantly less injection discomfort.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Transdermal               • 50 to 100 mg (1–2 pumps)          • Applied topically every morning to clean, dry skin
   Testosterone Gel (1–1.62%)  applied to shoulders/upper arms     of shoulders or upper arms (NEVER genitals).
                                                                 • RISK OF INTERPERSONAL TRANSFER: Must wash hands
                                                                   and cover area; keep away from children/partners.
   ───────────────────────────────────────────────────────────────────────────────────────────────────────────
   Testosterone Undecanoate  • 750 mg IM at 0, 4 weeks,          • Long-acting depot formulation; provides stable
   (Aveed)                     then every 10 weeks                 levels for months; boxed warning for PEMA (microembolism).
   ═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

Laboratory Monitoring & The Erythrocytosis Imperative

• Total Testosterone Monitoring: Measured every 3 months during the first year, then every 6 to 12 months.
  • For weekly injections: Check midway between injections (trough/mid-cycle; target $400–700\text{ ng/dL}$) or at trough just prior to the next injection ($>300–400\text{ ng/dL}$).
  • For transdermal gel: Check 2 to 8 hours after morning application.
• Hematocrit & Hemoglobin Monitoring (Critical ABFM Concept):
  • Testosterone directly stimulates renal erythropoietin (EPO) production and bone marrow erythropoiesis, while suppressing hepcidin (increasing iron availability).
  • Secondary Erythrocytosis (Polycythemia) is the most common dose-limiting adverse effect of testosterone therapy, occurring in up to 10–15% of patients.
  • Management Algorithm for Erythrocytosis:
    • Hematocrit $\le 50%$: Normal male range; continue maintenance regimen.
    • Hematocrit $50% - 54%$: Borderline elevation; monitor closely every 3 months; encourage smoking cessation and hydration; screen for obstructive sleep apnea.
    • Hematocrit $> 54%$: CRITICAL THRESHOLD. Markedly increases blood viscosity, microcirculatory sluggishness, and the risk of fatal ischemic stroke, deep vein thrombosis, and myocardial infarction.
    • Mandatory Clinical Interventions for Hct $> 54%$:
      1. Reduce testosterone dosage by 25–50% or switch from injectable depot to transdermal daily gel.
      2. Screen for and aggressively treat concurrent Obstructive Sleep Apnea (OSA) (testosterone worsens nocturnal airway collapse).
      3. Perform therapeutic phlebotomy (500 mL) if hematocrit remains $>54%$ despite dose reduction, to immediately restore safe rheology.
• Metabolic & Hepatic Monitoring: Check fasting lipid profile (testosterone may lower HDL and slightly increase LDL/triglycerides), liver biochemistries, and blood pressure at baseline and annually.

---

Reproductive Health & Fertility Counseling

1. Mandatory Fertility Preservation Counseling

Gender-affirming hormone therapies suppress the hypothalamic-pituitary-gonadal axis, leading to testicular atrophy and azoospermia in transfeminine individuals, and follicular arrest and amenorrhea in transmasculine individuals. While these effects are sometimes reversible upon medication discontinuation, long-term GAHT can cause permanent, irreversible germ cell damage and infertility.

• Guideline Mandate: Clinicians MUST discuss reproductive wishes and offer referrals for fertility preservation PRIOR to the initiation of any gender-affirming hormone therapy or gonadectomy.
• Options include:
  • For transfeminine individuals: Semen cryopreservation (sperm banking).
  • For transmasculine individuals: Oocyte or embryo cryopreservation (requires ovarian stimulation and transvaginal ultrasound-guided oocyte retrieval).

2. The Critical Contraceptive Rule: Testosterone is NOT Birth Control

[!CRITICAL] Testosterone is NOT a Contraceptive Although exogenous testosterone therapy induces amenorrhea in $>90%$ of transmasculine individuals within 3 to 6 months, intermittent, spontaneous ovulation CAN STILL OCCUR.

• Transgender men with an intact uterus and ovaries who engage in receptive penile-vaginal intercourse with sperm-producing partners are at significant risk for unintended pregnancy.
• Furthermore, exogenous testosterone is a potent teratogen causing virilization of a female fetus, craniofacial defects, and pregnancy loss.
• First-Line Contraceptive Options for Transmasculine Patients:
  • Levonorgestrel-releasing Intrauterine System (LNG-IUD): First-line; provides exceptionally high contraceptive efficacy ($>99.8%$), induces local endometrial decidualization, synergistically accelerates amenorrhea, and produces negligible systemic progestin levels that do NOT interfere with masculinization.
  • Copper Intrauterine Device (Cu-IUD): 100% hormone-free; highly effective; may cause increased cramping or breakthrough spotting.
  • Etonogestrel Subdermal Implant (Nexplanon): Progestin-only; excellent efficacy for 3–5 years; does not interfere with testosterone.
  • Progestin-Only Oral Pills (POPs; e.g., drospirenone or norethindrone): Safe and effective without estrogenic vascular risks.
  • Note: Estrogen-containing combined hormonal contraceptives (COCs, patch, ring) are generally avoided due to dysphoria and physiological feminization, although they are not medically contraindicated if patient prefers.